철결핍성 빈혈 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 치료 유형별, 치료 영역별, 최종사용자별, 지역별＆경쟁(2021-2031년)

The Global Iron Deficiency Anemia Market, comprising therapeutic solutions like oral and parenteral iron formulations aimed at replenishing iron stores and normalizing hemoglobin levels, is projected to grow from USD 5.89 Billion in 2025 to USD 9.18 Billion by 2031, exhibiting a 7.68% CAGR. This growth is primarily driven by the escalating burden of chronic diseases and maternal health conditions necessitating consistent hematological intervention, alongside increasing awareness of nutritional deficits, with updated 2025 estimates indicating that 30.7% of women aged 15-49 years were affected by anemia globally.

Market Driver

The increasing burden of Chronic Kidney Disease (CKD) and gastrointestinal disorders serves as a primary catalyst for market expansion, as these conditions frequently disrupt iron absorption and utilization, necessitating consistent iron supplementation for patients, exemplified by Akebia Therapeutics' Auryxia generating $152.2 million in net product revenues for full year 2024 in the renal care space. Concurrently, a heightened focus on maternal health and the management of pregnancy-related anemia significantly propels therapeutic adoption, with governmental and health organization mandates increasingly prioritizing screening and treatment; the World Health Organization reported that 35.5% of pregnant women aged 15-49 years worldwide were affected by anemia in 2023, which has spurred the uptake of novel oral formulations like Accrufer, reporting 153% year-over-year revenue growth to $29.3 million in 2024 for Shield Therapeutics.

Market Challenge

The adverse event profiles associated with standard iron replacement therapies present a direct and significant impediment to the Global Iron Deficiency Anemia Market's expansion. Oral iron formulations frequently induce severe gastrointestinal distress, leading to patient non-compliance and premature discontinuation, while intravenous administration carries risks of hypersensitivity reactions and necessitates clinical supervision, creating logistical obstacles that limit product uptake, especially in resource-constrained settings. These safety and tolerability issues prevent the market from fully capitalizing on the urgent therapeutic needs of high-risk demographics, such as the 35.5% of pregnant women aged 15-49 years globally affected by anemia, thereby restricting widespread adoption of effective iron therapies and hampering overall market revenue potential.

Market Trends

The market is witnessing an accelerated adoption of high-dose intravenous iron therapies, driven by the clinical need to streamline treatment protocols and minimize hospital visits by enabling complete iron repletion in a single administration, which significantly enhances outpatient efficiency, as reflected in Pharmacosmos' annual revenue surpassing DKK 3 billion, attributed to the global uptake of its high-dose monoferric formulation. Simultaneously, the competitive landscape is being reshaped by the market entry and expansion of biosimilar iron therapeutics, triggered by the expiration of patents for established branded intravenous treatments, which provides cost-effective options for healthcare systems and compels incumbents to adapt strategies, with CSL Limited reporting $527 million in iron product sales for the period, achieving volume growth despite intensifying generic competition.

Key Market Players

• AbbVie Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Amgen Inc.
• Bayer AG
• Fresenius Kabi AG
• Vifor Pharma Group
• Glenmark Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Ltd.

Report Scope

In this report, the Global Iron Deficiency Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Iron Deficiency Anemia Market, By Therapy Type

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion
• Others

Iron Deficiency Anemia Market, By Therapy Areas

• Obstetrics and Gynecology
• Oncology
• Congestive Heart Failure (CHF)
• Inflammatory Bowel Disease
• Renal
• Others

Iron Deficiency Anemia Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Iron Deficiency Anemia Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Market.

Available Customizations:

Global Iron Deficiency Anemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Iron Deficiency Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others)
  • 5.2.2. By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Iron Deficiency Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Therapy Areas
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Iron Deficiency Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Therapy Areas
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Iron Deficiency Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Therapy Areas
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Iron Deficiency Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Therapy Areas
      • 6.3.3.2.3. By End User

7. Europe Iron Deficiency Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Therapy Areas
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Iron Deficiency Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Therapy Areas
      • 7.3.1.2.3. By End User
  • 7.3.2. France Iron Deficiency Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Therapy Areas
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Iron Deficiency Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Therapy Areas
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Iron Deficiency Anemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Therapy Areas
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Iron Deficiency Anemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Therapy Areas
      • 7.3.5.2.3. By End User

8. Asia Pacific Iron Deficiency Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Therapy Areas
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Iron Deficiency Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Therapy Areas
      • 8.3.1.2.3. By End User
  • 8.3.2. India Iron Deficiency Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Therapy Areas
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Iron Deficiency Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Therapy Areas
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Iron Deficiency Anemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Therapy Areas
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Iron Deficiency Anemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Therapy Areas
      • 8.3.5.2.3. By End User

9. Middle East & Africa Iron Deficiency Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Therapy Areas
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Iron Deficiency Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Therapy Areas
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Iron Deficiency Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Therapy Areas
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Iron Deficiency Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Therapy Areas
      • 9.3.3.2.3. By End User

10. South America Iron Deficiency Anemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Therapy Areas
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Iron Deficiency Anemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Therapy Areas
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Iron Deficiency Anemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Therapy Areas
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Iron Deficiency Anemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Therapy Areas
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Iron Deficiency Anemia Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Takeda Pharmaceutical Company Limited
• 15.4. Novartis AG
• 15.5. Amgen Inc.
• 15.6. Bayer AG
• 15.7. Fresenius Kabi AG
• 15.8. Vifor Pharma Group
• 15.9. Glenmark Pharmaceuticals Ltd.
• 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer